prikaz prve stranice dokumenta Current trends in the pharmacotherapy for obesity
  Download
PDF 247.12 KB
Scientific paper - review paper
Current trends in the pharmacotherapy for obesity
Endocrine Oncology and Metabolism, 2 (2016), 1; 50-59. https://doi.org/10.21040/eom/2016.2.6
Klobučar Majanović, Sanja; Crnčević Orlić, Željka; Štimac, Davor

Cite this document

Klobučar Majanović, S., Crnčević Orlić, Ž. & Štimac, D. (2016). Current trends in the pharmacotherapy for obesity. Endocrine Oncology and Metabolism, 2. (1), 50-59. doi: 10.21040/eom/2016.2.6

Klobučar Majanović, Sanja, et al. "Current trends in the pharmacotherapy for obesity." Endocrine Oncology and Metabolism, vol. 2, no. 1, 2016, pp. 50-59. https://doi.org/10.21040/eom/2016.2.6

Klobučar Majanović, Sanja, Željka Crnčević Orlić and Davor Štimac. "Current trends in the pharmacotherapy for obesity." Endocrine Oncology and Metabolism 2, no. 1 (2016): 50-59. https://doi.org/10.21040/eom/2016.2.6

Klobučar Majanović, S., Crnčević Orlić, Ž. and Štimac, D. (2016) 'Current trends in the pharmacotherapy for obesity', Endocrine Oncology and Metabolism, 2(1), pp. 50-59. doi: 10.21040/eom/2016.2.6

Klobučar Majanović S, Crnčević Orlić Ž, Štimac D. Current trends in the pharmacotherapy for obesity. Endocrine Oncology and Metabolism [Internet]. 2016 [cited 2024 April 26];2(1):50-59. doi: 10.21040/eom/2016.2.6

S. Klobučar Majanović, Ž. Crnčević Orlić and D. Štimac, "Current trends in the pharmacotherapy for obesity", Endocrine Oncology and Metabolism, vol. 2, no. 1, pp. 50-59, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:359339. [Accessed: 26 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Current trends in the pharmacotherapy for obesity
AuthorSanja Klobučar Majanović
AuthorŽeljka Crnčević Orlić
AuthorDavor Štimac
Author's institutionUniversity of Rijeka
Faculty of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Obesity represents a major global challenge from both healthcare and economic perspectives. Although lifestyle modifications aimed at reducing calorie intake and increasing energy expenditure remain the cornerstone of obesity management, pharmacotherapy can serve as a useful adjunct. Until recently, orlistat was the only medication registered for the treatment of obesity in the European Union (EU). A deeper understanding of the complexity of energy homeostasis has resulted in new pharmacological options for weight reduction. In 2015, two new antiobesity drugs were approved in the EU. These are a fixed combination of naltrexone/bupropion (Mysimba®) and liraglutide at a dose of 3.0 mg (Saxenda®). In addition, lorcaserin (Belviq®) and a fixed combination of phentermine/topiramate (Qsymia®) were introduced into the US market in 2012. However, the European Medicines Agency did not approve their use in the EU. The burden of previous weight loss agents that have been withdrawn due to safety concerns underlines the need for caution and close follow-up of patients undergoing pharmacological interventions for obesity treatment. This article provides an overview of the efficacy and safety of currently available weight loss pharmacotherapies.
Keywords (english)
Languageenglish
Publication typeScientific paper - review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleEndocrine Oncology and Metabolism
Numberingvol. 2, no. 1, pp. 50-59
p-ISSN1849-8922
DOIhttps://doi.org/10.21040/eom/2016.2.6
URN:NBNurn:nbn:hr:184:359339
Publication2016
Document URLhttp://bib.irb.hr/812922
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2018-05-30 10:31:22